文献速递眼底病与葡萄膜炎

阿达木单抗治疗葡萄膜炎的药物保留率与停药原因:BioÚvea研究组真实世界数据

Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group.
PubMed 文献 · Ophthalmology · 2019-12-02

该多中心、全国性、注册登记、双向观察性研究分析了392例非感染性葡萄膜炎患者使用阿达木单抗的真实世界数据,中位随访49.07个月,中位药物保留时间69.3个月,6、12、24、60个月药物保留率分别为92.97%、87.68%、76.31%、54.28%。停药原因包括缺乏或失去疗效(74例)、不良事件(34例)和持续静止期(25例)。

要点

  • 阿达木单抗治疗葡萄膜炎60个月药物保留率为54.28%,安全性良好。
  • 合并使用经典免疫调节治疗未显著影响药物保留时间。
  • 阿达木单抗作为第二线或更后线生物治疗时药物保留时间更短(P=0.038)。

核心结论

  • 阿达木单抗治疗葡萄膜炎60个月药物保留率为54.28%,安全性良好。
  • 合并使用经典免疫调节治疗未显示对药物保留时间的显著影响。
  • 阿达木单抗作为第二线或更后线生物治疗可能预测因疗效不佳而停药。
  • 未分化葡萄膜炎可能易于因不良事件而提前停用阿达木单抗。

研究设计与样本

  • 多中心、全国性、注册登记、双向观察性研究。
  • 中位年龄39岁(四分位距25岁),非前部葡萄膜炎242例。
  • 中位随访49.07个月(范围0.97-131.67个月),14例失访。

主要发现

  • 6、12、24、60个月药物保留率分别为92.97%、87.68%、76.31%、54.28%。
  • 中位药物保留时间(生存)为69.3个月。
  • 151例停用阿达木单抗,其中因缺乏或失去疗效74例,不良事件34例,持续静止期25例。
  • 记录的不良事件包括感染10例和恶性肿瘤3例。
  • 合并经典免疫调节治疗251例,未发现药物保留时间差异。

关键数值与推荐

  • 药物保留率:6个月92.97%,12个月87.68%,24个月76.31%,60个月54.28%。
  • 中位药物保留时间:69.3个月。
  • 停药原因:缺乏或失去疗效74例,不良事件34例,持续静止期25例。
  • 不良事件:感染10例,恶性肿瘤3例。
  • 阿达木单抗作为第二线或更后线生物治疗与更短药物保留时间相关(P=0.038)。

临床怎么用

  • 在真实世界葡萄膜炎患者中,阿达木单抗60个月药物保留率为54.28%,安全性良好。
  • 合并使用经典免疫调节治疗未显著影响阿达木单抗的药物保留时间。
  • 对于非生物制剂初治患者,使用阿达木单抗作为第二线或更后线生物治疗时,应关注因疗效不佳而停药的风险。
  • 未分化葡萄膜炎患者可能因不良事件而提前停用阿达木单抗,需加强监测。

局限性

  • 本研究为观察性注册登记研究,可能存在未测量的混杂因素。
  • 随访期间有14例患者失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the drug retention rate (DRR), causes, and predictors of discontinuation of adalimumab (ADA) in a real-world uveitis setting. DESIGN: Multicentric, nationwide, registry-based, ambispective, observational study. PARTICIPANTS: Patients treated with ADA for noninfectious uveitis (NIU) in the Biotherapies for Uveitis (BioÚvea) Spanish registry from November 2016 to November 2017. METHODS: Demographics, clinical data, timing, and reasons for discontinuation, if occurred, were recorded. The DRR and drug retention time (DRT) were estimated using the Kaplan-Meier method. Median follow-up was analyzed by reverse Kaplan-Meier. Log-rank test was used for comparisons. Cox proportional-hazards model (PHM) and propensity score matching were used to identify predictors for discontinuation due to inefficacy and adverse events. MAIN OUTCOME MEASURES: Drug retention rate and DRT. RESULTS: A total of 392 patients were analyzed, including 218 women. Median age was 39 (interquartile range, 25) years. Nonanterior uveitis was recorded in 242 patients. Median follow-up was 49.07 (0.97-131.67) months, median DRT (survival) was 69.3 months, and 14 patients were lost to follow-up. The DRR at 6, 12, 24, and 60 months was 92.97%, 87.68%, 76.31%, and 54.28%, respectively. Adalimumab was discontinued in 151 patients. Discontinuation was due to lack or loss of efficacy in 74 patients, adverse event in 34 patients, and sustained quiescence in 25 patients. Recorded adverse events included infections in 10 patients and malignant neoplasms in 3 patients. Concurrent classic immunomodulatory therapy (IMT) was given to 251 patients. We did not find DRT differences regarding the use of concurrent IMT. Adalimumab was prescribed as a second or greater biotherapy line in 76 patients who showed shorter DRT (P = 0.038). Starting ADA in nonbiotherapy-naive patients was a predictor for "discontinuation due to inefficacy," whereas undifferentiated uveitis was a predictor for "discontinuation due to adverse event." Drug retention time was significantly shorter when spared or intensified, mainly due to discontinuation after sustained quiescence. CONCLUSIONS: Drug retention rate of ADA in uveitis at 60 months was 54.28%, with a good safety profile. The use of concurrent IMT did not show a significant influence on DRT. The use of ADA as a second or further biotherapy could be predictive for discontinuation due to inefficacy. Undifferentiated uveitis may be prone to premature discontinuation of ADA due to adverse events.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Llorenç V, Cordero-Coma M, Blanco-Esteban A, et al. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group. Ophthalmology. 2019. PMID: 31952883. doi:10.1016/j.ophtha.2019.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。